That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

An­oth­er Al­ler­gan project picked up by Ab­b­Vie in their $63 bil­lion buy­out has turned sour.

Uro­Gen $URGN re­port­ed Thurs­day morn­ing that a Phase II study us­ing their RT­Gel prod­uct to ap­ply Botox to stop over­ac­tive blad­der and uri­nary in­con­ti­nence has failed. Ab­b­Vie had been in charge of the study af­ter com­plet­ing the Al­ler­gan deal a few months ago.

Uro­Gen ex­ecs pinned the blame on Botox, say­ing that the da­ta sug­gest that the wrin­kle ther­a­py hadn’t ef­fec­tive­ly per­me­at­ed the urothe­li­um, or blad­der wall, pre­vent­ing ef­fi­ca­cy. And they went on to tout their prod­uct, al­ready on the mar­ket for urothe­lial can­cer, as a win­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER